<DOC>
	<DOCNO>NCT00526318</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy autologous stem cell transplant stop growth tumor cell stop divide kill . It also prepare patient 's bone marrow stem cell transplant . The stem cell give patient replace blood-forming cell destroy chemotherapy . Giving isotretinoin transplant may kill remain tumor cell . It yet know combination chemotherapy regimen effective give stem cell transplant isotretinoin treat neuroblastoma . PURPOSE : This randomized clinical trial study two different combination chemotherapy regimens compare well work give stem cell transplant isotretinoin treat young patient high-risk neuroblastoma .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Stem Cell Transplant Isotretinoin Treating Young Patients With High-Risk Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare event-free survival pediatric patient high-risk neuroblastoma treated standard induction chemotherapy vs topotecan hydrochloride-containing induction chemotherapy follow myeloablative autologous stem cell transplantation consolidation therapy isotretinoin . Secondary - Compare overall survival patient treat regimen . - Compare early response ( complete response , good partial response , partial response , mixed response , stable disease , progression/relapse ) 2 course standard v experimental induction chemotherapy ( 60 day second course yet finish ) . - Compare response standard v experimental induction chemotherapy autologous stem cell transplantation ( 280 day induction chemotherapy yet finish ) . - Compare toxicity standard v experimental induction chemotherapy course 1 2 frequency ≥ grade 3 toxicity last 6 course induction chemotherapy . - Compare extent initial surgery best surgery ( biopsy v incomplete resection v macroscopic complete resection ) frequency complication relate surgery ( e.g. , nephrectomy , bleeding , infection , intestinal obstruction ) . - Compare acute long-term side effect external-beam radiotherapy . - Correlate activity MIBG whole-body radiation dose . - Collect store tumor material tumor bank future evaluation molecular marker ( MYCN status chromosome 1p 11q ) prognostic significant gene signature . OUTLINE : This multicenter study . Patients stratify accord disease stage , lactate dehydrogenase ( LDH ) status , MYCN status , age diagnosis ( stage 4 disease ; LDH elevate ; MYCN status ; age diagnosis 1-21 year vs stage 4 disease ; LDH elevate ; MYCN status ; age diagnosis ≥ 1 &lt; 2 year vs stage 4 disease ; LDH elevate ; MYCN status ; age diagnosis 2-21 year vs localize disease ; MYCN amplification ; age diagnosis ≥ 6 month ) - Induction chemotherapy : Patients randomize 1 2 induction chemotherapy arm . - Arm I ( standard ) : Patients receive N5 chemotherapy comprise cisplatin IV continuously 96 hour etoposide phosphate IV continuously 96 hour day 1-4 vindesine IV 1 hour day 1 . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin day 9 continue blood count recover . Patients receive N6 chemotherapy comprise vincristine IV 1 hour day 1 8 , dacarbazine IV 1 hour day 1-5 , ifosfamide IV continuously 120 hour day 1-5 , doxorubicin hydrochloride IV 4 hour day 6 7 . Patients also receive G-CSF SC daily begin day 10 continue blood count recover . Treatment N5 N6 chemotherapy alternate every 21 day 6 course ( N5 chemotherapy give course 1 , 3 , 5 N6 chemotherapy give course 2 , 4 , 6 ) . - Arm II ( experimental ) : Patients receive N8 chemotherapy comprise cyclophosphamide IV 1 hour day 1-7 , topotecan hydrochloride IV continuously 168 hour day 1-7 , etoposide phosphate IV 1 hour day 8-10 . Patients also receive G-CSF SC daily begin day 12 continue blood count recover . Treatment N8 chemotherapy repeat every 21 day 2 course . Patients receive N5 chemotherapy alternate N6 chemotherapy arm I . - Surgery : Patients may undergo secondary surgery completion 4 6 course induction chemotherapy prior radiotherapy . - Radiotherapy ( 131I-MIBG therapy external-beam radiotherapy [ EBRT ] ) : Patients active residual primary tumor completion induction chemotherapy undergo ^131I-MIBG therapy* prior autologous stem cell transplantation ( ASCT ) EBRT ASCT . NOTE : *Patients MIBG negative neuroblastoma initial diagnosis receive EBRT . - Myeloablative ASCT : Patients receive melphalan IV 30 minute day -8 -5 , etoposide phosphate IV 4 hour day -4 , carboplatin IV 1 hour day -4 -2 . Patients undergo reinfusion CD34+ stem cell day 0 . Patients also receive G-CSF SC IV 4 hour daily begin day 2 continue blood count recover . - Consolidation therapy ( isotretinoin ) * : Beginning 30 day ASCT , patient receive oral isotretinoin daily day 1-14 . Treatment repeat every 28 day 6 course . Beginning 3 month later , patient receive additional 3 course isotretinoin . NOTE : *Isotretinoin must give concurrently radiotherapy After completion study treatment , patient follow every 6 week 1 year , every 3 month 4 year , every 6 month thereafter .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Vindesine</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis neuroblastoma accord follow criterion : Histological diagnosis tumor tissue Presence distinct neuroblastoma cell bone marrow elevate catecholamine metabolite ( HVA , VMA ) blood urine Highrisk disease , meet 1 follow criterion : Stage 4 disease , regardless MYCN status ( 121 year age ) Stage 13 4S disease MYCN amplification ( 6 month 21 year age ) PATIENT CHARACTERISTICS : Not pregnant nursing Fertile patient must use effective contraception ( hormonal contraception intrauterine device [ IUD ] ) PRIOR CONCURRENT THERAPY : No concurrent participation another clinical trial would preclude intervention outcome assessment clinical trial No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>localize resectable neuroblastoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
	<keyword>regional neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
</DOC>